Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 plus nab-paclitaxel and carboplatin as first-line therapy for advanced thymic carcinoma
ChiCTR2300072705Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, paclitaxel and carboplatin in thymic carcinoma (TC), sponsored by Shanghai Chest Hospital. Primary endpoint: objective response rate. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
adebrelimabpaclitaxelcarboplatin
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2300072705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072705.